Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
133.4 EUR | -0.24% | -4.07% | -4.89% |
28/05 | Sector Update: Health Care Stocks Fall Late Afternoon | MT |
28/05 | Sector Update: Health Care Stocks Retreat Tuesday Afternoon | MT |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's enterprise value to sales, at 3.85 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.89% | 347B | - | ||
+38.59% | 727B | C+ | ||
+15.66% | 319B | B- | ||
+0.24% | 274B | C+ | ||
+13.16% | 238B | B+ | ||
+7.06% | 204B | B- | ||
-6.46% | 203B | A+ | ||
+4.23% | 161B | C+ | ||
-1.70% | 160B | C+ | ||
-1.86% | 120B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- JNJ Stock
- 4JNJ Stock
- Ratings Johnson & Johnson